Atypical antipsychotics in the treatment of early-onset schizophrenia

Código QR

Atypical antipsychotics in the treatment of early-onset schizophrenia

Michal Hrdlicka, Iva Dudova Department of Child Psychiatry, Charles University Second Faculty of Medicine and University Hospital Motol, Prague, Czech Republic Abstract: Atypical antipsychotics (AAPs) have been successfully used in early-onset schizophrenia (EOS). This review summarizes the rando...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hrdlicka M, Dudova I
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/06b0293d55704c5dbf7922a4eb60d14f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia
por: Goto N, et al.
Publicado: (2012)

Serum substance P levels in patients with chronic schizophrenia treated with typical or atypical antipsychotics
por: Takahiko Nagamine
Publicado: (2008)

The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naïve first-episode patients with schizophrenia: a preliminary study
por: Gro&scaron;ić V, et al.
Publicado: (2014)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

The influence of atypical antipsychotic drugs on sexual function
por: Just MJ
Publicado: (2015)

Early-onset anorexia nervosa in girls with Asperger syndrome
por: Dudova I, et al.
Publicado: (2015)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

Olfactory functions are not associated with autism severity in autism spectrum disorders
por: Dudova I, et al.
Publicado: (2013)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa T, et al.
Publicado: (2011)

Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone
por: Hong Liu-Seifert, et al.
Publicado: (2009)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu X, et al.
Publicado: (2014)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto K, et al.
Publicado: (2014)

Altered heart rate dynamics associated with antipsychotic-induced subjective restlessness in patients with schizophrenia
por: Kim JH, et al.
Publicado: (2013)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari S, et al.
Publicado: (2015)

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
por: Izchak Kohen, et al.
Publicado: (2010)

Update on the role of antipsychotics in the treatment of Tourette syndrome
por: Huys D, et al.
Publicado: (2012)

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine
por: Kishi T, et al.
Publicado: (2014)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
por: Takahashi M, et al.
Publicado: (2012)

Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first- episode or multi-episode schizophrenia
por: Washida K, et al.
Publicado: (2013)

Psychiatrists' awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey
por: Olivares JM, et al.
Publicado: (2013)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels
por: Lozano Ortiz R
Publicado: (2012)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
por: Ishioka M, et al.
Publicado: (2015)

Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia
por: Frydecka D, et al.
Publicado: (2015)

Comparison of three screening tests for autism in preterm children with birth weights less than 1,500 grams
por: Dudova I, et al.
Publicado: (2014)

Markers of neurodevelopmental impairments in early-onset psychosis
por: Petruzzelli MG, et al.
Publicado: (2015)

Pharmacotherapy for treatment-resistant schizophrenia
por: Meghan E Mcilwain, et al.
Publicado: (2011)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin T, et al.
Publicado: (2013)

Early prediction of blonanserin response in Japanese patients with schizophrenia
por: Kishi T, et al.
Publicado: (2014)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb N, et al.
Publicado: (2012)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome L
Publicado: (2011)

New developments in the treatment of partial-onset epilepsy
por: Besag FM, et al.
Publicado: (2012)

Atypical antipsychotics-induced metabolic syndrome and nonalcoholic fatty liver disease: a critical review
por: Xu H, et al.
Publicado: (2019)

The Relationship Between Antipsychotic Treatment and Plasma β-Endorphin Concentration in Patients with Schizophrenia
por: Urban-Kowalczyk M, et al.
Publicado: (2021)

Safety and tolerability of switching to asenapine from other antipsychotic agents: pooled results from two randomized multicenter trials in stable patients with persistent negative symptoms in schizophrenia
por: Mackle M, et al.
Publicado: (2012)

Antipsychotics and risk of natural death in patients with schizophrenia
por: Chen Y, et al.
Publicado: (2019)

Profile of minocycline and its potential in the treatment of schizophrenia
por: Zhang L, et al.
Publicado: (2014)

Towards a framework for treatment effectiveness in schizophrenia
por: Juckel G, et al.
Publicado: (2014)

Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao YM, et al.
Publicado: (2015)